EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations

摘要

The standard care for head and neck squamous cell carcinoma (HNSCC) patients involving postoperative radiation therapy (RT) with concurrent cisplatin-based chemotherapy remains the same to this day since it’s conceptualization in the 1960s ( ). Though this treatment plan does improve locoregional control and disease-free survival in head and neck cancer patients, rates for overall 5-year survival is unimpressive in advanced HNSCC, ranging from 30% to 60%.